Clinical Effect of Revascularization Strategies and Pharmacologic Treatment on Long-Term Results in Patients with Advanced Peripheral Artery Disease with TASC C and D Femoropopliteal Lesions
Table 4
Cox regression analysis of primary patency.
Variable
Univariate
#Multivariate
HR (95% CI†)
value
ATE
value
Age (years)
1.02 (0.99–1.04)
0.208
Gender (F/M)
1.01 (0.7–1.77)
0.662
BMI
0.99 (0.94–1.04)
0.59
Smoking (yes/no)
1.36 (0.89–2.08)
0.155
Hyperlipidemia (yes/no)
0.97 (0.55–1.65)
0·902
CAD (yes/no)
0.95 (0.63–1.42)
0.798
Hypertension (yes/no)
1.06 (0.66–1.72)
0·799
DM (yes/no)
1.26 (0.81–1.96)
0.306
ESRD (yes/no)
1.06 (0.67–1.69)
0.805
Rutherford classification (V plus VI/III plus IV)
1.46 (0.87–2.46)
0.153
hsCRP (mg/L)
1.03 (0.99–1.67)
0.1
1.02 (0.98–1.0)
0.399
Diabetic neuropathy
2.03 (1.34–3.08)
0.001
0.94 (0.5–1.74)
0.824
Ischemia severity
ABI
1.26 (0.78–2.02)
0.341
Statin treatment (yes/no)
0.38 (0.24–0.62)
<0.001
0.54 (0.33–0.9)
0.017
Cilostazol treatment (>3 Ms/≤3 Ms)
0.33 (0.22–0.51)
<0.001
0.46 (0.3–0.72)
0.001
Insulin alone (yes/no)
2.12 (1.38–3.25)
0.001
1.6 (0.91–2.81)
0.106
Involved leg (L/R)
1.18 (0.82–1.7)
0.364
Intervention (bypass/stenting)
0.61 (0.41–0.92)
0.019
0.8 (0.52–1.22)
0.292
DR/IR
0.34 (0.22–0.53)
<0.001
0.47 (0.29–0.74)
0.001
#Multivariate, weighted Cox regression with average treatment effect (ATE), HR, hazard ratio; †CI, confidence interval. ABI, ankle brachial index; BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus; ESRD, end-stage renal disease; DR, direct revascularization; hsCRP: high-sensitivity C-reactive protein; HA1c: hemoglobin A1c; IR, indirect revascularization.
